Derbyshire Medicines Management and Clinical Policies
Home
Medicines Management
Full Traffic Light Classification
Show Drug
Amikacin (Arikayce)
Size guide:
A
A
A
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Deprescribing
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Inappropriate Requests and Prescribing Concerns in Primary Care
Print this page
Add shortcut to your smart phone
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Deprescribing
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Amikacin (Arikayce)
Search the site
Search
Status:
Red
Decision Date:
March 2021
Comments
RED
NICE ES36:
Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial lung infections caused by
Mycobacterium avium
complex in adults with limited treatment options who do not have cystic fibrosis. (Decision date - June 2021)
search again
Derby and Derbyshire ICB
